Caribou Biosciences, Inc. (CRBU)
CRBU Stock Price Chart
Explore Caribou Biosciences, Inc. interactive price chart. Choose custom timeframes to analyze CRBU price movements and trends.
CRBU Company Profile
Discover essential business fundamentals and corporate details for Caribou Biosciences, Inc. (CRBU) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Biotechnology
IPO Date
23 Jul 2021
Employees
147.00
Website
https://cariboubio.comCEO
Rachel E. Haurwitz
Description
Caribou Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the development of genome-edited allogeneic cell therapies for the treatment of hematologic malignancies and solid tumors in the United States and internationally. Its lead product candidates are CB-010, an allogeneic anti-CD19 CAR-T cell therapy that is in phase 1 clinical trial to treat relapsed or refractory B cell non-Hodgkin lymphoma; and CB-011, an allogeneic anti-BCMA CAR-T cell therapy for the treatment of relapsed or refractory multiple myeloma. The company also develops CB-012, an allogeneic anti-CD371 CAR-T cell therapy for the treatment of relapsed or refractory acute myeloid leukemia; and CB-020, an allogeneic CAR-NK cell therapy for the treatment of solid tumors. It has collaboration with AbbVie Manufacturing Management Unlimited Company to develop CAR-T cell therapies. The company was incorporated in 2011 and is headquartered in Berkeley, California.
CRBU Financial Timeline
Browse a chronological timeline of Caribou Biosciences, Inc. corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 5 Nov 2025
EPS estimate is -$0.35.
Earnings released on 12 Aug 2025
EPS came in at -$0.35 surpassing the estimated -$0.40 by +12.50%, while revenue for the quarter reached $2.67M , beating expectations by +74.09%.
Earnings released on 8 May 2025
EPS came in at -$0.43 matching the estimated -$0.43, while revenue for the quarter reached $2.35M , beating expectations by +27.09%.
Earnings released on 10 Mar 2025
EPS came in at -$0.39 surpassing the estimated -$0.40 by +2.50%, while revenue for the quarter reached $2.08M , missing expectations by -1.39%.
Earnings released on 6 Nov 2024
EPS came in at -$0.38 surpassing the estimated -$0.44 by +13.64%, while revenue for the quarter reached $2.02M , missing expectations by -34.23%.
Earnings released on 6 Aug 2024
EPS came in at -$0.42 surpassing the estimated -$0.45 by +6.67%, while revenue for the quarter reached $3.46M , beating expectations by +13.69%.
Earnings released on 7 May 2024
EPS came in at -$0.46 falling short of the estimated -$0.39 by -17.95%, while revenue for the quarter reached $2.43M , beating expectations by +0.51%.
Earnings released on 11 Mar 2024
EPS came in at -$0.39 falling short of the estimated -$0.22 by -77.27%, while revenue for the quarter reached $3.56M , missing expectations by -10.02%.
Earnings released on 7 Nov 2023
EPS came in at -$0.12 surpassing the estimated -$0.38 by +68.42%, while revenue for the quarter reached $23.66M , beating expectations by +618.85%.
Earnings released on 8 Aug 2023
EPS came in at -$0.48 surpassing the estimated -$0.49 by +2.04%, while revenue for the quarter reached $3.76M , beating expectations by +21.99%.
Earnings released on 9 May 2023
EPS came in at -$0.46 surpassing the estimated -$0.48 by +4.17%, while revenue for the quarter reached $3.50M , beating expectations by +27.35%.
Earnings released on 9 Mar 2023
EPS came in at -$0.44 surpassing the estimated -$0.47 by +6.38%, while revenue for the quarter reached $3.69M , beating expectations by +20.34%.
Earnings released on 8 Nov 2022
EPS came in at -$0.44 surpassing the estimated -$0.48 by +8.33%, while revenue for the quarter reached $3.30M , missing expectations by -10.73%.
Earnings released on 9 Aug 2022
EPS came in at -$0.46 falling short of the estimated -$0.37 by -24.32%, while revenue for the quarter reached $4.19M , beating expectations by +46.57%.
Earnings released on 9 May 2022
EPS came in at -$0.35 matching the estimated -$0.35, while revenue for the quarter reached $2.66M , missing expectations by -16.75%.
Earnings released on 21 Mar 2022
EPS came in at -$0.34 matching the estimated -$0.34, while revenue for the quarter reached $2.56M , missing expectations by -38.64%.
Earnings released on 9 Nov 2021
EPS came in at -$0.46 falling short of the estimated -$0.12 by -280.17%, while revenue for the quarter reached $3.98M , missing expectations by -75.90%.
Earnings released on 2 Sept 2021
EPS came in at -$1.55 falling short of the estimated $0.42 by -469.05%, while revenue for the quarter reached $1.48M .
Earnings released on 23 Jul 2021
EPS came in at -$0.48 , while revenue for the quarter reached $1.59M .
Earnings released on 31 Dec 2020
EPS came in at -$0.53 , while revenue for the quarter reached $984.00K .
Earnings released on 30 Sept 2020
EPS came in at -$0.29 , while revenue for the quarter reached $1.20M .
CRBU Stock Performance
Access detailed CRBU performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.